Cancer drugs

Cancer drugs

Drugs, agents used in the treatment of cancer or conditions related to cancer.

Contributors in Cancer drugs

Cancer drugs

An orally bioavailable small molecule, targeting the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. PDGFR inhibitor CP-868596 binds to and inhibits PDGFR, ...

Specific androgen receptor modulator/lyase inhibitor TOK-001

Pharmaceutical; Cancer drugs

An orally bioavailable small-molecule androgen receptor modulator and CYP17 lyase inhibitor with potential antiandrogen activity. TOK-001 exhibits three distinct mechanisms of action: 1) as an ...

BTK inhibitor PCI-32765

Pharmaceutical; Cancer drugs

An orally bioavailable small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. BTK inhibitor PCI-32765 binds to and inhibits BTK activity, preventing B-cell ...

CK2 inhibitor CX-4945

Pharmaceutical; Cancer drugs

An orally bioavailable small-molecule inhibitor of CK2 with potential antineoplastic activity. CK2 inhibitor CX-4945 selectively binds to and inhibits the enzyme casein kinase II (CK2), which may ...

JAK1/2 inhibitor CYT387

Pharmaceutical; Cancer drugs

An orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with potential antineoplastic activity. JAK1/2 inhibitor CYT387 competes with JAK1/2 for ATP binding, which may ...

MEK inhibitor AS703026

Pharmaceutical; Cancer drugs

An orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity. MEK inhibitor AS703026 selectively binds to and inhibits the activity of MEK1/2, ...

MEK inhibitor TAK-733

Pharmaceutical; Cancer drugs

An orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity. MEK inhibitor TAK-733 selectively binds to and inhibits the activity of MEK1/2, ...